PRISM BioLab & Elix join forces to speed up AI-driven drug discovery for protein-protein interaction targets: Tokyo, Japan Tuesday, April 15, 2025, 16:00 Hrs [IST] PRISM BioLab, C ...

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceu tical Co.

Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter "Elix"), an AI drug discovery company with the mission of "Rethinking Drug Discovery", today announced that it has entered into a drug discovery ...

Science & Technology近日，我院左涛研究员团队在Gut（IF=23.0）在线发表题为：Dietary whey protein protects against Crohn’s disease by orchestrating ...

For the first time, researchers have revealed the high-affinity interaction between mitochondrial proteins HAX1 ...

PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced ...

Scientists studying mice have uncovered a delicate protein rivalry in the brain that, when thrown off balance, may cause ...

A new study from Karolinska Institutet shows how a small antibody fragment can block fertilization by targeting a key protein on the surface of the egg.

A new study from Karolinska Institutet shows how a small antibody fragment can block fertilization by targeting a key protein ...